News Release

Highlights — Fourth Quarter and Full year ended December 31 2012.

• Quarter 4 net revenue increased 24% year on year to $300 million. Full Year 2012 net revenue increased 18% to $1.12 billion.
• Quarter 4 operating income was $24.4 million or 8.1% of revenue. Full Year 2012 operating income before non- recurring charges was $73.7 million or 6.6% of revenue.
• Earnings per share for Quarter 4 were $0.34. EPS for the full year 2012 before non-recurring charges was $1.00.
• Quarter 4 net business awards were $378 million, a book to bill of 1.26. Full Year net new business awards were $1.6 billion, a book to bill of 1.4.
• Backlog increased 20% year on year to $2.8 billion.
• Guidance increased to reflect the acquisition of the clinical trial service division of Cross Country Healthcare, Inc. to revenue in the range of $1,258 — $1,292 million and EPS in the range of $1.44 — $1.60.

DUBLIN--(BUSINESS WIRE)-- ICON plc, (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the full year and fourth quarter ended December 31, 2012.

For the fourth quarter net revenue grew 24% year on year to $300 million. Operating income was $24.4 million compared to $6.6 million in the same quarter last year. Operating margin was 8.1% of revenue, compared to 2.7% of revenue for the same quarter last year.

Net income was $20.7 million compared with $4.1 million last year or $0.34 per share compared to $0.07 in the same quarter last year.

For the full year revenue grew 18% to $1.12 billion. Operating income before restructuring and other items was $73.7 million compared to $39.3 million last year. Operating margin for the full year 2012 was 6.6% of revenue compared with 4.2% of revenue in 2011.

On a US GAAP basis, income from operations was $68.0 million or 6.1% compared with $29.4 million or 3.1% in the prior year.

For the full year net income before restructuring and other items was $60.4 million, compared to $31.5 million last year and net margin was 5.4% of revenue, compared with 3.3% in 2011.

EPS before restructuring and other items for 2012 was $1.00 per share compared with $0.52 in 2011.

On a US GAAP basis net income was $55.4 million, compared to $22.8 million last year. Net margin for the full year 2012 was 5.0% of revenue, up from 2.4% in 2011. EPS on a US GAAP basis for 2012 was $0.92 per share compared with $0.37 in 2011.

Days sales outstanding, comprising accounts receivable and unbilled revenue less payments on account were 40 days at December 31, 2012 compared with 47 days at December 31, 2011.

For the quarter ended December 31, 2012, cash provided by operating activities was $12.0 million and capital expenditure was $8.4 million. For the full year 2012 cash flow from operating activities was $113.4 million and capital expenditure was $30.8 million. In addition $69.9 million was invested on acquisitions and $15.8 million was expended on a stock repurchase programme. As a result the company's net cash amounted to $190 million at December 31, 2012 compared to $174 million of net cash at December 31, 2011.

On the 15^th of February we completed the acquisition of the clinical trial service division of Cross Country Healthcare, Inc. This will be combined with our DOCS group to create a global leader in resourcing. Consequently we have increased our full year guidance to revenue in the range of $1,258- $1,292 and EPS in the range of $1.44 - $1.60.

CEO Ciaran Murray commented, "In 2012 we saw the validation of our investment strategy as we won a record $1.6 billion of new business and reported milestone revenue of $1.12 billion and EPS of $1.00. Backlog grew 20% to $2.8 billion, which along with continuing investment in capabilities, talent and innovation in drug development, provides a solid foundation for further growth in 2013."

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this press release contains certain non-GAAP financial measures, including non-GAAP operating and net income and non-GAAP diluted earnings per share. While non-GAAP financial measures are not superior to or a substitute for the comparable GAAP measures, ICON believes certain non-GAAP information is useful to investors for historical comparison purposes.

ICON will hold its fourth quarter conference call today, February 19, 2013 at 9:00 EST [14:00 Ireland & UK]. This call and linked slide presentation can be accessed live from our website at http://investor.iconplc.com. A recording will also be available on the website for 90 days following the call. In addition, a calendar of company events, including upcoming conference presentations, is available on our website, under "Investors". This calendar will be updated regularly.

The statements made in this press release may contain forward-looking statements that involve a number of risks and uncertainties. In addition to the matters described in this press release, the ability to maintain large client contracts or enter into new contracts, maintain client relationships and the ability to manage the opening of new offices, the integration of new business mergers and acquisitions, as well as other risks and uncertainties detailed from time to time in reports filed with the US Securities and Exchange Commission by ICON, including its Form 20-F, F-1, S-8 and F-3, may affect the actual results achieved by ICON. ICON disclaims any intent or obligation to update these forward-looking statements.

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 79 locations in 37 countries and has approximately 10,045 employees. Further information is available at www.iconplc.com.

ICON/ICLR-F

ICON plc
Consolidated Income Statements (Unaudited)
(Before restructuring and other items)
Three and Twelve Months ended December 31, 2012 and December 31, 2011
(Dollars, in thousands, except share and per share data)
		Three Months Ended				Twelve Months Ended
		December 31,		December 31,		December 31,		December 31,
		2012		2011		2012		2011
Gross Revenue		406,353		337,934		1,503,993		1,296,509
Reimbursable expenses		106,189		95,319		388,987		350,780
Net Revenue		300,164		242,615		1,115,006		945,729
Costs and expenses
Direct costs		192,007		158,244		717,750		611,923
Selling, general and administrative		73,165		67,008		280,780		255,864
Depreciation and amortization		10,590		10,713		42,823		38,682
Total costs and expenses		275,762		235,965		1,041,353		906,469
Income from operations		24,402		6,650		73,653		39,260
Net interest expense		(278)		(751)		(796)		(448)
Income before provision for income taxes		24,124		5,899		72,857		38,812
Provision for income taxes		(3,377)		(1,786)		(12,506)		(7,347)
Net income		20,747		4,113		60,351		31,465
Net income per ordinary share
Basic		$0.35		$0.07		$1.00		$0.52
Diluted		$0.34		$0.07		$1.00		$0.52
Weighted average number of ordinary shares
Basic		60,053,987		60,371,190		59,968,174		60,379,338
Diluted		60,813,483		60,759,588		60,450,706		61,070,686

ICON plc
Consolidated Income Statements (Audited)
(US GAAP)
Three and Twelve Months ended December 31, 2012 and December 31, 2011
(Dollars, in thousands, except share and per share data)
		Three Months Ended				Twelve Months Ended
		December 31,		December 31,		December 31,		December 31,
		2012		2011		2012		2011
Gross Revenue		406,353		337,934		1,503,993		1,296,509
Reimbursable expenses		106,189		95,319		388,987		350,780
Net Revenue		300,164		242,615		1,115,006		945,729
Costs and expenses
Direct costs		192,007		158,244		717,750		611,923
Selling, general and administrative		73,165		67,008		280,780		255,864
Depreciation and amortization		10,590		10,713		42,823		38,682
Restructuring and other items		-		-		5,636		9,817
Total costs and expenses		275,762		235,965		1,046,989		916,286
Income from operations		24,402		6,650		68,017		29,443
Net interest expense		(278)		(751)		(796)		(448)
Income before provision for income taxes		24,124		5,899		67,221		28,995
Provision for income taxes		(3,377)		(1,786)		(11,801)		(6,115)
Net income		20,747		4,113		55,420		22,880
Net income per ordinary share
Basic		$0.35		$0.07		$0.92		$0.38
Diluted		$0.34		$0.07		$0.92		$0.37
Weighted average number of ordinary shares
Basic		60,053,987		60,371,190		59,968,174		60,379,338
Diluted		60,813,483		60,759,588		60,450,706		61,070,686

ICON plc
Summary Balance Sheet Data
December 31, 2012 and December 31, 2011
(Dollars, in thousands)
		December 31,		December 31,
		2012		2011
		(Audited)		(Audited)
Net cash		190,230		174,177
Accounts receivable		285,419		201,338
Unbilled revenue		112,483		126,850
Payments on account		(219,467)		(150,792)
Total		178,435		177,396
Working Capital		239,791		253,514
Total Assets		1,211,330		1,035,467
Shareholder's Equity		754,575		681,544

ICON plc
Investor Relations 1-888-381-7923 or
Brendan Brennan Chief Financial Officer +353—1-291-2000
Sam Farthing VP Investor Relations +353—1-291-2000
Simon Holmes EVP Investor Relations and Corporate Development +353—1-291-2000
All at ICON

Source: ICON plc

News Provided by Acquire Media